Stage II Breast Cancer
120
7
20
63
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
46 trials with published results (38%)
Research Maturity
63 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
24 terminated out of 120 trials
72.4%
-14.1% vs benchmark
8%
9 trials in Phase 3/4
73%
46 of 63 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 63 completed trials
Clinical Trials (120)
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Researching the Effect of Exercise on Cancer
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Acupuncture Pilot Study for Cancer-related Cognitive Function
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Improving Exercise Capacity With a Tailored Physical Activity Intervention
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
A Study of Revaree Plus in People With Breast Cancer
Window of Opportunity Study Targeting the Inflammatory Milieu
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer